Document is current
Any future updates will be listed below
-
Authors
Bailey, Stefanie R
Bartee, Eric https://orcid.org/0000-0003-1793-446X
Daniels, Kyle G
Heery, Christopher R
Kaumaya, Pravin https://orcid.org/0000-0002-8647-3911
Lesinski, Gregory B https://orcid.org/0000-0002-8787-7678
Lowinger, Timothy B
Nelson, Michelle H
Rubinstein, Mark P
Wittling, Megen C https://orcid.org/0000-0002-3631-4955
Paulos, Chrystal M
Posey, Avery D Jr https://orcid.org/0000-0001-8711-629X
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04460456 at ClinicalTrials.govnct05091528 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
393 A phase 1/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers
https://doi.org/10.1136/jitc-2021-sitc2021.393
Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells
https://doi.org/10.1136/jitc-2021-004268
Where does ISAC (immune-stimulating antibody conjugates) go from here?
https://doi.org/10.1136/jitc-2025-012500
nct05954143 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Where does ISAC (immune-stimulating antibody conjugates) go from here?
https://doi.org/10.1136/jitc-2025-012500
nct05514717 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd).
https://doi.org/10.1200/jco.2024.42.16_suppl.tps1121
Where does ISAC (immune-stimulating antibody conjugates) go from here?
https://doi.org/10.1136/jitc-2025-012500
nct05070247 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies
https://doi.org/10.1136/jitc-2025-011572
654 XMT-2056: a phase 1 study of a HER2-directed STING agonist antibody drug conjugate (ADC) in HER2+ solid tumors
https://doi.org/10.1136/jitc-2024-sitc2024.0654
Where does ISAC (immune-stimulating antibody conjugates) go from here?
https://doi.org/10.1136/jitc-2025-012500
1053 XMT-2056, a HER2-targeted immunosynthen STING agonist antibody-drug conjugate, induces anti-tumor activity at low doses in preclinical models
https://doi.org/10.1136/jitc-2024-sitc2024.1053
nct04420884 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer
https://doi.org/10.1136/jitc-2022-006170
1153 Preclinical activity of C-C chemokine receptor 2 (CCR2)-targeted immune stimulating antibody conjugate (ISAC), motivating clinical testing of TAK-500
https://doi.org/10.1136/jitc-2022-sitc2022.1153
nct06060613 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
778 Phase 1b study of dazostinag plus pembrolizumab after hypofractionated radiotherapy in patients with non-small-cell lung cancer, triple-negative breast cancer, or head and neck squamous-cell carcinoma
https://doi.org/10.1136/jitc-2024-sitc2024.0778
Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies
https://doi.org/10.1136/jitc-2025-011572
1022 Evaluating the mechanism of enhanced responses to the IV STING agonist dazostinag (TAK-676) plus pembrolizumab in neuroendocrine tumors
https://doi.org/10.1136/jitc-2024-sitc2024.1022
Reversible downregulation of HLA class I in adenoid cystic carcinoma
https://doi.org/10.1136/jitc-2024-011380
nct05470283 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors.
https://doi.org/10.1200/jco.2024.42.16_suppl.tps9599
457 Engineered tumor-infiltrating lymphocytes (TIL) with co-regulated membrane-bound IL15 (mbIL15) and LIGHT (TNFSF14) generate significant antitumor efficacy in fibrotic tumor models
https://doi.org/10.1136/jitc-2024-sitc2024.0457
nct01174121 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma
https://doi.org/10.1136/jitc-2023-006822
OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma.
https://doi.org/10.1200/jco.2024.42.16_suppl.9515
348 TIL engineered with membrane-bound IL15 (cytoTIL15™) are enriched for tumor-associated antigen reactivity and demonstrate pharmacologically tunable expansion and persistence in the presence of TAA
https://doi.org/10.1136/jitc-2023-sitc2023.0348
457 Engineered tumor-infiltrating lymphocytes (TIL) with co-regulated membrane-bound IL15 (mbIL15) and LIGHT (TNFSF14) generate significant antitumor efficacy in fibrotic tumor models
https://doi.org/10.1136/jitc-2024-sitc2024.0457
nct05573035 at ClinicalTrials.govDocuments that mention this clinical trial
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
https://doi.org/10.1136/jitc-2025-013285
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Specific recognition of an <i>FGFR2</i> fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma
https://doi.org/10.1136/jitc-2022-006303
Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response
https://doi.org/10.1136/jitc-2025-014644
Utilization of primary tumor samples for cancer neoantigen discovery
https://doi.org/10.1136/jitc-2024-010993
Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes
https://doi.org/10.1136/jitc-2023-008645
Deregulation of HLA-I in cancer and its central importance for immunotherapy
https://doi.org/10.1136/jitc-2021-002899
Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
https://doi.org/10.1136/jitc-2021-002595
1216 Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
https://doi.org/10.1136/jitc-2023-sitc2023.1216
184 Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers
https://doi.org/10.1136/jitc-2021-sitc2021.184
nct05361174 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
747 Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors
https://doi.org/10.1136/jitc-2023-sitc2023.0747
nct04426669 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma
https://doi.org/10.1136/jitc-2023-006822
783 Trial in progress: a phase 1/2 open-label study (IOV-GM1–201) of TALEN-mediated PD-1–inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC
https://doi.org/10.1136/jitc-2022-sitc2022.0783
nct03726515 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma
https://doi.org/10.1136/jitc-2023-006822
Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity
https://doi.org/10.1136/jitc-2021-004244
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
https://doi.org/10.1136/jitc-2022-005845
333 Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program
https://doi.org/10.1136/jitc-2020-sitc2020.0333
nct05057715 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Advances in the management of glioblastoma
https://doi.org/10.1136/jnnp-2020-325334
Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions
https://doi.org/10.1136/jitc-2025-012308
nct04381741 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model
https://doi.org/10.1136/jitc-2022-006509
nct04539444 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
CARs are sharpening their weapons
https://doi.org/10.1136/jitc-2023-008275
nct05000450 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
nct05007379 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
nct04660929 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
nct06224738 at ClinicalTrials.govDocuments that mention this clinical trial
Engineering macrophages for effective and safe targeting of CD47 cancer cells in the tumor microenvironment
https://doi.org/10.1136/jitc-2025-014457
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors
https://doi.org/10.1136/jitc-2025-014592
315 Characterization of CT-0508, an anti-HER2 chimeric antigen receptor macrophage (CAR-M), manufactured from patients enrolled in the phase 1, first in human, clinical trial of CT-0508
https://doi.org/10.1136/jitc-2022-sitc2022.0315
A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors.
https://doi.org/10.1200/jco.2023.41.16_suppl.tps2666
Adoptively transferred macrophages for cancer immunotherapy
https://doi.org/10.1136/jitc-2024-010437
CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies
https://doi.org/10.1136/jitc-2021-002741
Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia
https://doi.org/10.1136/jitc-2023-007705
nct04405778 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
nct05164666 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Updated results from first-in-human phase 1 dose-escalation trial of TAK-102, a GPC3-targeted armored CAR T cells, in patients with advanced solid tumors.
https://doi.org/10.1200/jco.2024.42.16_suppl.2543
737 Interim results of a first-in-human phase 1 dose-escalation trial of TAK-102, a glypican-3 targeted armored chimeric antigen receptor T-cell immunotherapy in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2022-sitc2022.0737
320 Quantitative clinical pharmacology and mechanistic modeling of TAK-102, a GPC3 targeted CAR-T therapy armored with IL-7 and CCL19, in a phase-1 clinical trial in solid tumor patients
https://doi.org/10.1136/jitc-2024-sitc2024.0320
Documents that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
- License Information
